BNP Paribas Financial Markets
CATX icon

BNP Paribas Financial Markets’s Perspective Therapeutics CATX Stock Holding History

BNP Paribas Financial Markets’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.3K Buy
21,661
+9,151
+73% +$38.7K ﹤0.01% 4426
2025
Q4 		$34.4K Sell
12,510
-91,226
-88% -$260K ﹤0.01% 4847
2025
Q3 		$356K Sell
103,736
-138,874
-57% -$506K ﹤0.01% 3735
2025
Q2 		$835K Buy
242,610
+168,448
+227% +$445K ﹤0.01% 3025
2025
Q1 		$158K Buy
74,162
+23,068
+45% +$69.2K ﹤0.01% 3835
2024
Q4 		$163K Buy
51,094
+3,529
+7% +$28.8K ﹤0.01% 3971
2024
Q3 		$635K Buy
47,565
+44,174
+1,303% +$587K ﹤0.01% 2747
2024
Q2 		$33.8K Buy
3,391
+3,387
+84,675% +$49K ﹤0.01% 3548
2024
Q1 		$45 Hold
4
– – ﹤0.01% 3986
2023
Q4 		$15 Hold
4
– – ﹤0.01% 3981
2023
Q3 		$10 Hold
4
– – ﹤0.01% 3889
2023
Q2 		$25 Sell
4
-12
-75% -$73 ﹤0.01% 3886
2023
Q1 		$101 Buy
+16
New +$65 ﹤0.01% 3778
2014
Q3 		– Sell
-167
Closed -$5.2K – 4107
2014
Q2 		$5.2K Hold
167
– – ﹤0.01% 2562
2014
Q1 		$4.02K Hold
167
– – ﹤0.01% 2460
2013
Q4 		$834 Buy
+167
New +$880 ﹤0.01% 3865

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Financial Markets's CATX Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Perspective Therapeutics (CATX) stake by 73% in Q1 2026, buying an estimated $38.7K and bringing the position to 21,661 shares worth $90.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4426.

BNP Paribas Financial Markets first reported a position in CATX in Q4 2013 and has held it in 16 quarters since. The position peaked at $835K in Q2 2025. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • BNP Paribas Financial Markets held 21,661 shares of Perspective Therapeutics worth $90.3K as of Q1 2026.
  • BNP Paribas Financial Markets bought 9,151 Perspective Therapeutics shares in Q1 2026, an estimated $38.7K.
  • Perspective Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4426 holding.
  • BNP Paribas Financial Markets first reported a position in Perspective Therapeutics in Q4 2013 and has held it in 16 quarters since.
  • BNP Paribas Financial Markets's Perspective Therapeutics position peaked at $835K in Q2 2025.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.